ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

11,298Medicare Part D Prescriptions Filled, Including Refills

Rank: 189 out of 680

$717K Total Retail Price of All Prescriptions

Rank: 152 out of 680

663 Patients Receiving at Least One Drug in Part D
90%Patients 65 Years and Older
13% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Louisiana
Lower avg

Schedule Two
Controlled Substances

2% of this provider’s 663 patients filled at least one prescription for a schedule two drug, compared to an average of 3%.

Schedule Three
Controlled Substances

15% of this provider’s 663 patients filled at least one prescription for a schedule three drug, compared to an average of 14%.

Risky Drugs to Seniors

1% of this provider’s 10,272 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

22% of this provider’s prescriptions were for brand-name drugs, compared to an average of 26%.

Prescription Price

$64 was the average price of a prescription from this provider, compared to $59 among peers.

Prescriptions per Patient

17 is the average number of prescriptions (including refills) per patient, compared to an average of 22.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Louisiana
SIMVASTATIN 616 570 1 3
LEVOTHYROXINE SODIUM 604 572 2 2
LISINOPRIL 483 443 3 5
HYDROCODONE-ACETAMINOPHEN 392 337 S3 4 4
AMLODIPINE BESYLATE 334 306 5 1
METFORMIN HCL 308 289 6 8
ALPRAZOLAM 307 295 7 72
ZOLPIDEM TARTRATE 281 243 8 17
ATORVASTATIN CALCIUM 274 252 9 11
ALENDRONATE SODIUM 231 225 10 32
HYDROCHLOROTHIAZIDE 217 209 11 9
OMEPRAZOLE 208 186 12 7
FENOFIBRATE 203 175 13 66
LISINOPRIL-HYDROCHLOROTHIAZIDE 186 168 14 37
PRAVASTATIN SODIUM 158 136 15 10
LORAZEPAM 158 157 15 125
ATENOLOL 153 133 17 19
LOVASTATIN 150 144 18 44
METOPROLOL SUCCINATE 143 133 19 13
METOPROLOL TARTRATE 142 138 20 12
JANUVIA 132 130 21 60
PANTOPRAZOLE SODIUM 131 124 22 30
GLIPIZIDE ER 122 108 23 108
DIOVAN 120 116 24 31
POTASSIUM CHLORIDE 119 111 25 14
TRIAMTERENE-HCTZ 113 107 26 52
LEVOFLOXACIN 109 84 27 97
CLOPIDOGREL 104 102 28 26
NEXIUM 100 92 29 16
GABAPENTIN 98 90 30 15
ALLOPURINOL 96 83 31 33
FLUTICASONE PROPIONATE 96 76 31 41
CEFUROXIME 91 77 33 179
ENALAPRIL MALEATE 90 86 34 65
FUROSEMIDE 83 75 35 6
FINASTERIDE 83 79 35 109
GEMFIBROZIL 77 72 37 106
DIOVAN HCT 75 66 38 55
PLAVIX 72 67 39 39
ESCITALOPRAM OXALATE 70 69 40 45
EVISTA 70 70 40 135
TAMSULOSIN HCL 68 63 42 34
DONEPEZIL HCL 67 62 43 27
AMLODIPINE BESYLATE-BENAZEPRIL 61 61 44 43
SERTRALINE HCL 56 47 45 28
TRAMADOL HCL 55 54 46 18
CRESTOR 54 54 47 25
INSULIN SYRINGE 54 42 47 86
VERAPAMIL ER 53 44 49 100
CLONAZEPAM 52 27 50 190
LANSOPRAZOLE 51 51 51 184
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Dec. 28, 2010.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.